---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-357968"
form_type: "8-K"
ticker: "BMRN"
cik: "0001048477"
company_name: "BIOMARIN PHARMACEUTICAL INC"
filed_at: "2021-12-15T23:59:59+00:00"
generated_at: "2026-06-28T00:45:51.260529+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# BioMarin appoints Mark J. Alles to Board of Directors, effective Jan 1, 2022

## Summary
- Board size increased from ten to eleven members; Alles appointed to Board and Audit Committee.
- Appointment effective January 1, 2022; conditions satisfied December 10, 2021.
- Alles to receive standard independent director compensation and pro rata RSU grant ($400,000 annual value).
- No arrangement or understanding with any person for the appointment; no related party transactions.

## SEC filing metadata
- accession: 0001193125-21-357968
- form_type: 8-K
- ticker: BMRN
- cik: 0001048477
- company_name: BIOMARIN PHARMACEUTICAL INC
- filed_at: 2021-12-15T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1048477/000119312521357968/0001193125-21-357968-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1048477/000119312521357968/d265991d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-357968
- JSON: https://secwatch.observer/filing/0001193125-21-357968.json
- Plain text: https://secwatch.observer/filing/0001193125-21-357968.txt

## Key facts
- Executive change
  Mark J. Alles was appointed as Director at BIOMARIN PHARMACEUTICAL INC.
  - Action: appointed
  - Role: Director
  source text: appointed Mark J. Alles to the Board and to the Audit Committee of the Board, to be effective January 1, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1048477/000119312521357968/0001193125-21-357968-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.